Two years back, Emma Dimley, a Minnesota resident, found herself facing stage 4 colon cancer and was told it was incurable. Fast forward to today, she’s healthy and cancer-free, crediting a clinical trial as the lifeline she needed.
At just 23, Emma began experiencing severe abdominal pain, which led to an abnormal blood test. A subsequent colonoscopy uncovered tumors that were significantly large—one was even described as “softball-sized.”
After undergoing extensive treatments, including multiple surgeries, chemotherapy, and radiation, her cancer, which seemed resistant to treatment, had spread throughout her body. Emma recounts this period as a particularly challenging “low point” in her journey.
“I was pretty much just getting by for about four years,” she reflected in a recent interview. “I was just waiting for a clinical trial.” Now 35, she recalls the moment she learned about a new trial at the University of Minnesota—this was a no-brainer for her.
A Glimmer of Hope?
Once she learned about the trial, she felt an instant connection. “From day one, I was all in,” she remembers.
Led by Dr. Emil Lou, the trial focused on experimental gene therapy, which the researchers view as the next step for immunotherapy. Traditional immunotherapy tends to target external factors, but this approach works internally, targeting the cancer cells directly.
“Certain blocks within the cells hinder the immune system from acting against cancer,” Dr. Lou explained. “Think of it as a protective shield for cancer cells.”
As part of the trial, researchers gathered cancer cells from participants, tweaked them using CRISPR-CAS9 gene-editing technology—a sort of genetic “scissors”—to enhance the effectiveness of the immune response. These altered cells were then injected back into the participants’ bodies.
Emma emphasized, “They trained the cells to specifically attack my cancer after reintroduction.”
“What we observed was an unprecedented reaction,” she added.
Of course, there were hurdles along the way, including some tough side effects. “Focus on the positives,” Emma advised. “I had a fantastic support system around me.”
Among the 12 trial participants, Emma recorded the most remarkable outcomes.
“Unprecedented Success”
Dr. Lou noted that most advanced colorectal cancers are typically not deemed curable. He added, “Chemotherapy or available treatments are often palliative; they simply prolong patient lives but don’t eliminate the cancer.” However, Emma fit into a different category after beginning the trial.
Her response to the experimental immunotherapy was labeled “remarkable.” Remarkably, she was declared cancer-free after just one injection of the modified cells—a feat described as nearly unprecedented in cases of advanced colorectal cancer.
Dr. Lou explained, “We refer to this as a ‘complete clinical response’ in oncology, seen in less than 10% of all patients, particularly those with stage 4 colorectal cancer.”
Reflecting on her experience two years after participating in the trial, Emma says she feels great. “The treatment worked quickly, with no signs of illness,” she shared. Though she’s cautious about using terms like “cure,” she admits the trial has significantly shifted her perspective on cancer.
“Before, I thought remission was the best I could hope for. I had to be ready for the possibility of it returning, even if scans showed no signs. But now, my scans keep improving.”
Emma recently shared her story at the American Cancer Research Association (AACR) Annual Meeting in Chicago. Dr. Lou remarked, “Emma’s case is exceptional, but we’ve learned from her. Our goal is to replicate her success for future patients.”
The Importance of Early Detection
Recent studies suggest that colorectal cancer cases amongst those under 50 will see a surge, possibly doubling by 2030. Dr. Lou emphasized the need for early screening—blood tests, stool tests, and colonoscopies can save lives.
Since 2018, guidelines have changed to recommend screenings as early as age 45. Dr. Lou noted, “In recent years, I’ve noticed cases popping up in much younger patients. Just last week, someone in their early 40s was diagnosed with stage 4 colorectal cancer.”
Emma remains optimistic about raising awareness and promoting community engagement around early signs of colon cancer. “It’s vital to inform and stay connected without causing panic,” she concluded.
She also highlighted the role of genetic testing in identifying potential treatments, emphasizing, “It can be crucial in understanding your cancer type. I was fortunate to have the right kind for this therapy.”
